Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Volcano Takes Advantage Of Competitors' Trials To Tout FFR, IVUS

This article was originally published in The Gray Sheet

Executive Summary

Intravascular imaging device-maker Volcano is talking up the results of two trials presented at the TCT conference, although it was not the primary sponsor of either of them
Advertisement

Related Content

St. Jude Diversifies In Intra-Coronary Assessment Market With $90 Mil. Buy
St. Jude Diversifies In Intra-Coronary Assessment Market With $90 Mil. Buy
Lift-Off Time For LipiScan? Data And Payment Policies Will Tell
Lift-Off Time For LipiScan? Data And Payment Policies Will Tell
Lift-Off Time For LipiScan? Data And Payment Policies Will Tell
Fractional flow in PCI
Fractional flow in PCI
New Occlusion Devices May Fill Innovation Gap – CTO Summit Panel
Holiday Shopping: St. Jude Adds To A-Fib, Cardio Units With Two Acquisitions
Holiday Shopping: St. Jude Adds To A-Fib, Cardio Units With Two Acquisitions

Topics

Advertisement
UsernamePublicRestriction

Register

MT028007

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel